Interview with Karl Hübler, CEO, Eucodis Bioscience
Previously you worked for a pharmaceutical company, before moving to head up Eucodis Bioscience. What was your main…
Address: Viehmarktgasse 2 a/ 2. OG, 1030 Wien,Austria
Tel: + 43 1 8900804
Web: http://www.eucodisbioscience.com/web/index.php
EUCODIS Bioscience is an application-driven enzyme engineering company with customers in the pharmaceutical, biotechnology, diagnostics, and other industries. We manufacture and market over 50 well-characterized enzymes worldwide.
LacBusterTM is a β-lactamase specifically designed for environmental monitoring and sterility testing of a broad spectrum of β-lactam antibiotics with significantly higher activity than that of other products currently on the market.
Addressing its customers’ needs, EUCODIS Bioscience also provides various custom services, ranging from process development to routine protein manufacturing up to the kg scale across various industrial sectors.
The biotechnology and pharmaceutical industry is constantly seeking novel enzymes for API synthesis, replacing complex chemical reactions with biocatalysts. Other applications of enzymes include the white biotechnology industry, where enzymes play a significant role in the development of new formulations for laundry detergents, animal feeds, functional foods, cosmetics, and numerous other areas.
EUCODIS Bioscience has established itself as a leader in manufacturing novel enzymes for such applications. These enzymes are carefully selected to include the desired properties, such as chiral and regioselectivity, broader ranges of temperature and pH profiles, among other desired properties, making them suitable across various disciplines.
These recombinant enzymes can be supplied from as little as 50mg to the gram scale as crude extracts. Possible target enzymes (hits) can be supplied in kilogram quantities on demand at a short notice. Further up-scaling is done on a customer basis.
Previously you worked for a pharmaceutical company, before moving to head up Eucodis Bioscience. What was your main…
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz –…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics,…